Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Exelixis, Inc. EXEL
$19.19
-$0.16 (-0.83%)
На 18:00, 12 мая 2023
+35.49%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
6237555673.00000000
-
week52high
22.47
-
week52low
14.87
-
Revenue
1611062000
-
P/E TTM
35
-
Beta
0.67958400
-
EPS
0.56000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 20:00
Описание компании
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Overweight | Overweight | 26 июл 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 15 июл 2022 г. |
| BMO Capital | Outperform | 24 июн 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 18 февр 2022 г. |
| RBC Capital | Outperform | Outperform | 03 ноя 2021 г. |
| JMP Securities | Market Outperform | 18 окт 2022 г. | |
| RBC Capital | Outperform | Outperform | 02 ноя 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 02 ноя 2022 г. |
| EF Hutton | Buy | 01 ноя 2022 г. | |
| JMP Securities | Market Outperform | Market Outperform | 09 дек 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 19 янв 2023 г. |
| EF Hutton | Buy | Buy | 11 янв 2023 г. |
| Credit Suisse | Outperform | 26 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| MORRISSEY MICHAEL | A | 1340320 | 37994 | 30 янв 2023 г. |
| MORRISSEY MICHAEL | D | 340655 | 37994 | 30 янв 2023 г. |
| MORRISSEY MICHAEL | D | 0 | 100000 | 24 янв 2023 г. |
| MORRISSEY MICHAEL | D | 378649 | 62006 | 24 янв 2023 г. |
| MORRISSEY MICHAEL | A | 440655 | 100000 | 24 янв 2023 г. |
| Aftab Dana | A | 353001 | 100000 | 05 янв 2023 г. |
| Lamb Peter | D | 20000 | 20000 | 15 дек 2022 г. |
| Lamb Peter | D | 410958 | 20000 | 15 дек 2022 г. |
| Lamb Peter | A | 430958 | 20000 | 15 дек 2022 г. |
| MORRISSEY MICHAEL | A | 1302326 | 106010 | 07 дек 2022 г. |
Institutional Ownership
Institutional Ownership
| Holder | Shares | Change | Date Reported |
|---|---|---|---|
| DIMENSIONAL FUND ADVISORS LP | 4035449 | 255886 | 30 сент 2022 г. |
| Vanguard Total Stock Market Index Fund | 8636060 | -99171 | 31 авг 2020 г. |
| iShares Core S&P Mid-Cap ETF | 8115910 | -38161 | 31 авг 2020 г. |
| iShares NASDAQ Biotechnology ETF | 3147910 | -29202 | 31 авг 2020 г. |
| Vanguard Small-Cap Index Fund | 7623120 | -56020 | 31 июл 2020 г. |
| Vanguard Small-Cap Growth Index Fund | 4637690 | -21231 | 31 июл 2020 г. |
| Vanguard Extended Market Index Fund | 4350940 | -31589 | 31 июл 2020 г. |
| Fidelity Select Biotechnology Portfolio | 4098240 | 1649490 | 31 июл 2020 г. |
| T. Rowe Price New Horizons Fund | 4950570 | 1024440 | 30 июн 2020 г. |
| T. Rowe Price Health Sciences Fund | 4615820 | 850128 | 30 июн 2020 г. |
Новостная лента
Exelixis (EXEL) Q1 Earnings Miss, Revenues Increase Y/Y
Zacks Investment Research
10 мая 2023 г. в 15:59
Exelixis (EXEL) misses first quarter 2023 earnings and sales estimates, but product sales increase year over year.
Compared to Estimates, Exelixis (EXEL) Q1 Earnings: A Look at Key Metrics
Zacks Investment Research
09 мая 2023 г. в 22:09
The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Exelixis (EXEL) Lags Q1 Earnings and Revenue Estimates
Zacks Investment Research
09 мая 2023 г. в 20:37
Exelixis (EXEL) came out with quarterly earnings of $0.16 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.21 per share a year ago.
Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
Business Wire
25 апр 2023 г. в 16:05
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2023 financial results will be released on Tuesday, May 9, 2023 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon regist.
EXEL or ILMN: Which Is the Better Value Stock Right Now?
Zacks Investment Research
25 апр 2023 г. в 12:57
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?